Phaseline

Companies › Renaissance Pharma

Renaissance Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
hu14.18K322A
monoclonal anti-GD2 antibody
GD2Phase 2High-Risk NeuroblastomaMar 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07549321hu14.18K322APhase 2High-Risk NeuroblastomaOncologyMar 2031

Targets

GD2 (1)

Companies with the same targets

Beijing Biotech Merck KGaA

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.